Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Commissioner McClellan? HHS’ Thompson Says Nomination Is Imminent

This article was originally published in The Tan Sheet

Executive Summary

The Bush Administration appears ready to move forward with the nomination of health advisor Mark McClellan, MD/PhD, as FDA commissioner

You may also be interested in...



FDA Nominee McClellan Would Cement Agency’s Ties To Bush White House

The nomination of White House advisor Mark McClellan, MD/PhD, as FDA commissioner ensures the agency will continue its close alignment with Bush Administration priorities

Senate Health Committee Eyes October Hearing For McClellan

The Senate Health Committee appears to be fast-tracking the confirmation process for FDA commissioner nominee Mark McClellan, MD/PhD

FDA Nominee McClellan Would Cement Agency’s Ties To Bush White House

The nomination of White House advisor Mark McClellan, MD/PhD, as FDA commissioner ensures the agency will continue its close alignment with Bush Administration priorities

Related Content

Topics

UsernamePublicRestriction

Register

PS094555

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel